Core Viewpoint - Wanbangde Pharmaceutical's Alzheimer's project has been selected for a national major science and technology project led by the Shanghai Institute of Materia Medica, indicating strong governmental support for innovative drug development in China [1][2] Group 1: Project Details - Wanbangde Pharmaceutical's subsidiary has received approval from the National Health Commission for its Alzheimer's disease project, which is part of a national major science and technology project aimed at developing innovative drugs for high-prevalence diseases [1] - The project focuses on the industrialization and clinical research of "Shisuanjianma Controlled Release Tablets," which is a key component of the clinical evaluation and innovative product research [1][2] Group 2: Market Context - There are nearly 17 million Alzheimer's disease and related dementia patients in China, highlighting a significant market need for effective treatments [2] - The national major science and technology project aims to encourage the development of urgently needed innovative drugs and establish a self-controlled national drug research and development system [1][2] Group 3: Clinical Research - The clinical research for Shisuanjianma Controlled Release Tablets is currently in a large-scale, high-quality Phase II/III trial, designed as a multi-center, randomized, double-blind study with placebo and positive control groups [2] - This study is notable for being the first in China to set dual primary efficacy endpoints and to use Aβ-PET imaging to observe amyloid protein deposition changes, which will help assess the drug's potential to delay disease progression [2] Group 4: Implications for the Company - The inclusion of Shisuanjianma Controlled Release Tablets in the national major science and technology project reflects recognition of its potential clinical value and Wanbangde Pharmaceutical's capabilities in drug development and clinical research [2] - Successful implementation of the research tasks is expected to enhance the company's technological level and market competitiveness in the field of neurodegenerative disease drug development, positively impacting the clinical development and industrialization of its pipeline drugs [2]

Core Viewpoint - Wanbangde Pharmaceutical's Alzheimer's project has been selected for a national major science and technology project led by the Shanghai Institute of Materia Medica, indicating strong governmental support for innovative drug development in China [1][2] Group 1: Project Details - Wanbangde Pharmaceutical's subsidiary has received approval for its Alzheimer's disease project under the national major science and technology project, which focuses on breakthroughs in core technologies and the development of strategic products [1] - The project aims to address the urgent clinical needs for innovative drugs targeting major chronic diseases, infectious diseases, and rare diseases [1] Group 2: Clinical Research - The company is developing a new drug, Shisuanjianma Controlled-Release Tablets, specifically for Alzheimer's disease, which is currently undergoing large-scale, high-quality Phase II/III clinical trials [2] - The clinical study employs a multi-center, randomized, double-blind, and placebo-controlled design, aiming to comprehensively evaluate the drug's efficacy and safety [2] - This study is notable for being the first in China to set dual primary efficacy endpoints and to utilize Aβ-PET imaging to observe amyloid protein deposition changes [2] Group 3: Implications for the Company - The inclusion of Shisuanjianma Controlled-Release Tablets in the national major science and technology project reflects the recognition of its potential clinical value and the company's research capabilities in the field [2] - This project is expected to enhance the company's technological level and market competitiveness in the development of drugs for neurological diseases [2] - Successful implementation of the research tasks will facilitate the comprehensive execution of related innovative drug clinical trials, ultimately benefiting a large number of Alzheimer's patients [2]

万邦德医药控股集团股份有限公司 关于子公司阿尔茨海默病项目入选创新药物研发国家科技 重大专项的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 万邦德医药控股集团股份有限公司（以下简称"公司"）全资子公司万邦德 制药集团有限公司（以下简称"万邦德制药"）阿尔茨海默病项目入选了由中国 科学院上海药物研究所牵头的创新药物研发国家科技重大专项项目，已收到国家 卫生健康委员会中国生物技术发展中心下发的立项批复。 国家科技重大专项是为了实现国家目标，通过核心技术突破和资源集成，在 一定时限内完成的重大战略产品、关键共性技术和重大工程，是我国科技发展的 重中之重。创新药物研发国家科技重大专项聚焦"高发重大慢病、重大传染性疾 病、儿童疾病、罕见病和特殊场景创新药物"的用药需求，旨在鼓励研制临床亟 需的重磅创新药物、推动建立自主可控的国家创新药物研发体系。 证券代码：002082 证券简称：万邦德 公告编号：2026-002 国内首个设置双主要疗效终点并检测 Aβ-PET 影像学以观察淀粉样蛋白沉积变 化的高标准注册研究，项目还将观察患者治疗后疾病分期以验证其延缓疾病进展 ...

Core Viewpoint - Wanbangde's subsidiary, Wanbangde Pharmaceutical Group, has been selected for a national major science and technology project led by the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, focusing on innovative drug development for Alzheimer's disease [1] Group 1 - The Alzheimer's disease project involves the development of a new drug, Shisuanjianma Controlled-Release Tablets, which is currently undergoing large-scale, high-quality key registration Phase II/III clinical studies [1]

Core Viewpoint - Wanbangde's subsidiary has been selected for a significant national project focused on innovative drug development for Alzheimer's disease, indicating a strategic advancement in the company's research capabilities [1] Group 1 - Wanbangde Pharmaceutical Group has been awarded a project under the National Major Science and Technology Project for Innovative Drug Development led by the Shanghai Institute of Materia Medica, Chinese Academy of Sciences [1] - The project has received formal approval from the National Health Commission's China Biotechnology Development Center, highlighting governmental support for the initiative [1]

Market Overview - The Traditional Chinese Medicine (TCM) sector saw a slight increase of 0.31% on January 8, with WoHua Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4082.98, down 0.07%, while the Shenzhen Component Index closed at 13959.48, down 0.51% [1] Top Performers - WoHua Pharmaceutical (002107) closed at 7.13, up 5.63% with a trading volume of 298,400 shares and a turnover of 210 million yuan [1] - Enwei Pharmaceutical (301331) closed at 29.06, up 5.52% with a trading volume of 29,600 shares and a turnover of 85 million yuan [1] - Jinhua Co., Ltd. (600080) closed at 8.03, up 4.69% with a trading volume of 137,600 shares and a turnover of 110 million yuan [1] Underperformers - Jilin Aodong (000623) closed at 20.04, down 2.48% with a trading volume of 206,000 shares and a turnover of 416 million yuan [2] - Panlong Pharmaceutical (002864) closed at 34.32, down 1.58% with a trading volume of 149,000 shares and a turnover of 524 million yuan [2] - RY Pharmaceutical (600332) closed at 25.04, down 1.57% with a trading volume of 486,000 shares and a turnover of 122 million yuan [2] Capital Flow - The TCM sector experienced a net outflow of 493 million yuan from institutional investors, while retail investors saw a net inflow of 378 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors are actively buying [2] Individual Stock Capital Flow - Huaren Sanjiu (6660000) had a net inflow of 57.91 million yuan from institutional investors, while it faced a net outflow of 51.38 million yuan from speculative funds [3] - Yunnan Baiyao (000538) saw a net inflow of 42.56 million yuan from institutional investors, but also experienced outflows from both speculative and retail investors [3] - Wanbangde (002082) had a net inflow of 26.36 million yuan from institutional investors, with outflows from speculative and retail investors [3]

Group 1 - The core viewpoint of the news is that Wanbangde's stock has experienced fluctuations, with a recent decline of 2.07% and a total market value of 8.405 billion yuan [1] - As of January 7, the stock price is reported at 13.74 yuan per share, with a trading volume of 65.4153 million yuan and a turnover rate of 0.85% [1] - The company has seen a net outflow of main funds amounting to 8.6265 million yuan, with significant selling pressure from large orders [1] Group 2 - For the year-to-date, Wanbangde's stock has decreased by 1.36%, but has increased by 10.18% over the past 20 days [1] - The company reported a revenue of 1.018 billion yuan for the first nine months of 2025, reflecting a year-on-year decrease of 5.28%, and a net profit of 4.4678 million yuan, down 90.22% year-on-year [2] - The company has distributed a total of 613 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [3] Group 3 - Wanbangde's main business segments include medical devices (41.63% of revenue), chemical raw materials and preparations (24.69%), other goods (19.61%), and traditional Chinese medicine (14.07%) [1] - The company is classified under the pharmaceutical and biotechnology sector, specifically in traditional Chinese medicine [1] - As of September 30, the number of shareholders decreased by 32.75% to 26,400, while the average number of circulating shares per person increased by 48.70% to 20,944 shares [2]

证券代码：002082 证券简称：万邦德 公告编号：2026-001 万邦德医药控股集团股份有限公司 关于实际控制人部分股份质押及解除质押的公告 公司控股股东、实际控制人及其一致行动人保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 万邦德医药控股集团股份有限公司（以下简称"公司"）近日收到公司实际 控制人赵守明先生及庄惠女士的通知，获悉其所持有公司的部分股份办理了质押 及解除质押手续，具体事项如下： 二、股东股份解除质押基本情况 1.公司控股股东及其一致行动人本次质押与上市公司生产经营需求无关。 2.公司控股股东及实际控制人不存在未来半年内或一年内到期的质押股份。 3.公司控股股东及其一致行动人不存在非经营性资金占用、违规担保等侵害 上市公司利益的情形。 4.截至本公告披露日，公司控股股东及其一致行动人的股份质押事项对公司 生产经营、公司治理等未产生实质性影响，也不涉及业绩补偿义务。 公司将持续关注实际控制人及其一致行动人质押情况及质押风险，并及时进 行披露，敬请投资者谨慎决策 ...

Group 1 - The core focus of the news is the initiation of a Phase I clinical trial for Wanbangde Pharmaceutical Group's oral solution and injection of Huperzine A, aimed at comparing their pharmacokinetic characteristics in healthy Chinese subjects [1] - The clinical trial is designed as a single-center, randomized, open-label, single-dose, two-period, two-sequence, crossover study, with a registration number of CTR20255231 and the first public information date set for December 30, 2025 [1] - The primary objective of the trial is to compare the pharmacokinetic profiles of the oral solution and injection of Huperzine A under fasting conditions, while secondary objectives include assessing the relative bioavailability of the oral solution and the safety of both formulations [1] Group 2 - The main endpoints of the trial include pharmacokinetic parameters such as Cmax, AUC0-t, and AUC0-∞, while secondary endpoints include Tmax, λz, t1/2, AUC_%Extrap, CL/F, Vz/F, relative bioavailability F, physical examinations, vital signs, 12-lead ECG, laboratory tests, and adverse events [2] - The current status of the trial is ongoing, with a target enrollment of 20 participants, although recruitment has not yet started [2]

Market Overview - The Chinese medicine sector experienced a decline of 0.32% on December 30, with *ST Changyao leading the drop [1] - The Shanghai Composite Index closed at 3965.12, down 0.0%, while the Shenzhen Component Index closed at 13604.07, up 0.49% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Taiji Group (600129) with a closing price of 18.25, up 2.07% [1] - Wanbangde (002082) at 13.89, up 1.98% [1] - Fangsheng Pharmaceutical (603998) at 11.29, up 1.62% [1] - Conversely, *ST Changyao (300391) saw a significant drop of 19.49%, closing at 0.95 [2] Trading Volume and Value - The trading volume and value for key stocks were as follows: - Taiji Group: 87,200 shares traded, with a transaction value of 159 million [1] - Wanbangde: 164,400 shares traded, with a transaction value of 227 million [1] - Fangsheng Pharmaceutical: 48,000 shares traded, with a transaction value of 53.82 million [1] Capital Flow - The Chinese medicine sector experienced a net outflow of 231 million from institutional investors, while retail investors saw a net inflow of 280 million [2] - The capital flow for specific stocks included: - Wanbangde with a net inflow of 48.79 million from institutional investors [3] - Taiji Group with a net inflow of 18.53 million from institutional investors [3] - *ST Changyao had a net outflow of 19.49% [2]